View clinical trials related to Epilepsy.
Filter by:Epilepsy is a disease that requires long-term treatment and follow-up. Epilepsy To be successful in management, the educational needs of the patient must first be determined and the individual Treatment compliance should be increased by ensuring self-management of the disease.Interventions planned based on the model in patient education direct caregivers to specific goals and provide more planned, coordinated and safe care. The Health Promotion Model (HGM), developed by Nola Pender, is one of the models used to explain health protection and promotion behaviors. It is not aimed at preventing any disease or disability, but aims to improve health, in other words, to further increase the general health and well-being of the individual. H0: Web-based education given to epilepsy patients according to the Health Promotion Model has no effect on self-management. H1: Web-based education given to epilepsy patients according to the Health Promotion Model has an effect on self-management. Research Inclusion Criteria: 1. Individuals who agree to participate in the research 2. Being over 18 years of age 3. Having been diagnosed with epilepsy for at least 1 year 4. Being able to use technological devices (phone, computer, tablet) 5. Having internet access, 6. Being able to speak Turkish, 7. Not having any additional disease 8. Being literate When starting the study, patients who apply to the outpatient clinic and meet the inclusion criteria will be given an explanation about the purpose of the research and how the research process will work. Then, written consent will be obtained indicating that they agree to participate in the study. Pretest data will be collected online. "Personal Information Form" and "Epilepsy Self-Management" scale will be used for individuals in the control and experimental groups to collect data. In preparing the infrastructure of the web-based training program, a website called "Epilepsy Training Program" will be created with support from a professional computer engineering company. The training will include topics such as epilepsy, seizure management, medication management, safety management and lifestyle management. A training program consisting of presentations and videos will be offered on the website for a total of 4 weeks. 3 months after the training is completed, the "Epilepsy Self-Management Scale" will be applied to the experimental and control groups as a posttest.
Epilepsy is defined as a chronic disorder that presents with recurrent episodes of unprovoked seizures. Epileptic seizures are caused by excessive excitation of cortical neurons. The condition has various etiologies and comorbidities. Classification; The Classification of Epilepsies includes several diagnostic levels (steps): 1. from seizure type to epilepsy type (generalized/focal/combined generalized and focal/unknown) 2. etiology (genetic/ structural/ infectious/ metabolic/ immune/unknown). A clinician can use any level of the classification
The purpose of this research study Is to determine the accuracy and reliability of the wearable device in a controlled environment. This study will inform patients, healthcare professionals, and the wider community of the accuracy of the device in detecting seizures.
The goal of this clinical trial is to learn about the low glycemic index diet in pregnant people with epilepsy. The main questions it aims to answer are: - Is the low glycemic index tolerable in pregnant people with epilepsy? - Does the low glycemic index alter seizure frequency in pregnant people with epilepsy? - Does the low glycemic index alter the gut bacteria & associated metabolic pathways in pregnant people with epilepsy? Participants will start the low glycemic index diet during pregnancy and will provide stool and blood samples a maximum of 3 times during study duration. Researchers will compare pregnant people with epilepsy on the diet to pregnant people with epilepsy not on a structured diet plan to see if tolerability, seizure frequency, and gut bacteria composition & metabolites differ.
Optimizing treatments in mental health requires an easy to obtain, continuous, and objective measure of internal mood. Unfortunately, current standard-of-care clinical scales are sparsely sampled, subject to recency bias, underutilized, and are not validated for acute mood monitoring. The recent shift to remote care also requires novel methods to measure internal mood. Recent advances in computer vision have allowed the accurate quantification of observable speech patterns and facial representations. The continuous and objective nature of these audio-facial behavioral outputs also enable the study of their neural correlates. Here, the investigators hypothesize that video-derived audio-facial behaviors have discrete neural representations in the limbic network and can provide a critical set of reliable longitudinal estimates of mood at low cost across home and clinic settings.
This is an open-label, single-centre study to evaluate the clinical efficacy, safety and tolerability of Flunarizine administered as adjunctive treatment in participants diagnosed with treatment resistant absence epilepsy. The study goal is to see how efficient and safe flunarizine is at decreasing the frequency of absence seizures in children with treatment-resistant refractory epilepsy at doses of 5mg and 10mg once daily.
This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in patients with Developmental and Epileptic Encephalopathies (DEEs). The EAP study will allow continued treatment with LP352 for eligible patients diagnosed with treatment resistant DEEs who successfully completed an LP352 Clinical Trial (Enrollment by Invitation).
SLC13A5 deficiency (Citrate Transporter Disorder, EIEE 25) is a rare genetic disorder with neurodevelopmental delays and seizure onset in the first few days of life. This natural history study is designed to address the lack of understanding of disease progression. Additionally it will identify clinical and biomarker endpoints for use in future clinical trials.
The study will investigate whether a novel method to accurately count epileptic seizures, using a CE-marked minimally-invasive ultra long-term subcutaneous electroencephalography (EEG) solution (UNEEG™ SubQ , including 24/7 EEG SubQ), (i) is more accurate than a participant-reported seizure diary; (ii) is feasible and acceptable to participants and clinicians; (iii) reduces impacts of epilepsy and improves quality-of-life; and (iv) provides gains to the healthcare system when rolled-out into the National Health Service (NHS). 33 participants with drug-resistant epilepsy will be implanted with the UNEEG™ SubQ device and will collect data for six months. Annotated seizures from the EEG data will be sent weekly to the treating clinicians, who will communicate with the participants on a monthly basis, and will be free to make any management changes.
In epileptic and non Epileptic children, the full dentition of each patient was split into four quadrants, starting from the upper right quadrant (1) and moving clockwise until the lower right quadrant (4). Bundled into two groups: quadrant (1+3) vs. (2+4). After randomization, each of these pairs of quadrants had the same treatment modality; test quadrants received treatment with airflow to remove soft biofilm, and ultrasonic scaler for areas with calculus deposits, and control quadrants were treated with conventional rubber cup polishing to remove soft biofilm and ultrasonic scaler for calculus deposits.